IO Biotech Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance

IO Biotech Inc. has received a notice from the Nasdaq Stock Market indicating that its common stock has traded below the $1.00 minimum bid price requirement for 30 consecutive trading days, putting the company out of compliance with Nasdaq Listing Rule 5450(a)(1). The company has been granted a 180-day period, until June 16, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive trading days. If IO Biotech does not meet this requirement, it may be eligible for an additional 180-day compliance period by transferring its listing to the Nasdaq Capital Market, subject to meeting certain criteria. Failure to regain compliance could result in the company’s stock being delisted from Nasdaq. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IO Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-327089), on December 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here